ACO UPDATE

Scripps Accountable Care Organization (ACO) Board

Kevin Hirsch, MD, Chair

Dan Dworsky, MD

Scott Eisman, MD

C. Lucy Polak, MD

Robert Sarnoff, MD

Robert Tjosvold

Jon Worsey, MD

_____

ACO Chief Executive
Barbara Price
price.barbara@scrippshealth.org
858-678-6017

ACO Chief Medical Officer
Anil Keswani, MD
keswani.anil@scrippshealth.org
858-927-5331

ACO Primary Contact
Cindy Gipson
gipson.cynthia@scrippshealth.org
858-678-7478

Quality Reporting Part 1

The traditional equation for population health is:

$$\text{Population Health} = \underline{\frac{\text{Quality Performance Outcomes} \times \text{Service}}{\text{Cost}}}$$

Quality typically only played a supporting role in healthcare contracting. Quality performance now takes center stage. Success in the MSSP program requires that we bend the cost curve AND meet performance standards on 34 measures.

ACO savings = Quality Performance × Savings Achieved.

We want to familiarize you with the 34 measures that span 4 quality domains:

- Patient Experience of Care
- Care Coordination/Patient Safety
- Preventive Health
- At-Risk Population management

Please see attachment for full list of measures. The measures align with the programs like Physician Quality Reporting System (PQRS) and the Electronic Health Record (EHR) Incentive Programs. Please look for additional information in Part 2 of our Quality Reporting update.

For performance year 2017, quality reporting will be completed in the first quarter of calendar year 2018. We will work collaboratively with provider offices to ensure our mutual success on quality performance.

Table: 33 ACO Quality Measures

Domain	Measure	Description	Pay-for-Performance Phase In R= Reporting P= Performance		
			PY1	PY2	PY3
Patient/Caregiver Experience	ACO #1	Getting Timely Care, Appointments, and Information	R	P	P
Patient/Caregiver Experience	ACO #2	How Well Your Doctors Communicate	R	P	P
Patient/Caregiver Experience	ACO #3	Patients' Rating of Doctor	R	P	P
Patient/Caregiver Experience	ACO #4	Access to Specialists	R	P	P
Patient/Caregiver Experience	ACO #5	Health Promotion and Education	R	P	P
Patient/Caregiver Experience	ACO #6	Shared Decision Making	R	P	P
Patient/Caregiver Experience	ACO #7	Health Status/Functional Status	R	R	R
Care Coordination/Patient Safety	ACO #8	Risk Standardized, All Condition Readmissions	R	R	P
Care Coordination/Patient Safety	ACO #9	ASC Admissions: COPD or Asthma in Older Adults	R	P	P
Care Coordination/Patient Safety	ACO #10	ASC Admission: Heart Failure	R	P	P
Care Coordination/Patient Safety	ACO #11	Percent of PCPs who Qualified for EHR Incentive Payment	R	P	P
Care Coordination/Patient Safety	ACO #12	Medication Reconciliation	R	P	P
Care Coordination/Patient Safety	ACO #13	Falls: Screening for Fall Risk	R	P	P
Preventive Health	ACO #14	Influenza Immunization	R	P	P
Preventive Health	ACO #15	Pneumococcal Vaccination	R	P	P
Preventive Health	ACO #16	Adult Weight Screening and Follow-up	R	P	P
Preventive Health	ACO #17	Tobacco Use Assessment and Cessation Intervention	R	P	P
Preventive Health	ACO #18	Depression Screening	R	P	P
Preventive Health	ACO #19	Colorectal Cancer Screening	R	R	P
Preventive Health	ACO #20	Mammography Screening	R	R	P
Preventive Health	ACO #21	Proportion of Adults who had blood pressure screened in past 2 years	R	R	P
At-Risk Population Diabetes	Diabetes Composite ACO #22 – 26	ACO #22. Hemoglobin A1c Control (HbA1c) (<8 percent) ACO #23. Low Density Lipoprotein (LDL) (<100 mg/dL) ACO #24. Blood Pressure (BP) < 140/90 ACO #25. Tobacco Non Use ACO #26. Aspirin Use	R	P	P
At-Risk Population Diabetes	ACO #27	Percent of beneficiaries with diabetes whose HbA1c in poor control (>9 percent)	R	P	P
At-Risk Population Hypertension	ACO #28	Percent of beneficiaries with hypertension whose BP < 140/90	R	P	P
At-Risk Population IVD	ACO #29	Percent of beneficiaries with IVD with complete lipid profile and LDL control < 100mg/dl	R	P	P
At-Risk Population IVD	ACO #30	Percent of beneficiaries with IVD who use Aspirin or other antithrombotic	R	P	P
At-Risk Population HF	ACO #31	Beta-Blocker Therapy for LVSD	R	R	P
At-Risk Population CAD	CAD Composite ACO #32 – 33	ACO #32. Drug Therapy for Lowering LDL Cholesterol ACO #33. ACE Inhibitor or ARB Therapy for Patients with CAD and Diabetes and/or LVSD	R	R	P

Notes: PY = Performance Year